Skip to main content

Author: Customer Service

Technip Energies secures major contract for Coral Norte floating LNG project in Mozambique

Coral Norte FLNGCoralNorte_TechnipEnergiesTechnip Energies (PARIS:TE), in partnership with JGC and Samsung Heavy Industries, has been awarded an Engineering, Procurement, Construction, Installation & Commissioning (EPCIC) contract by Mozambique Rovuma Venture (MRV) for the Coral Norte FLNG project, which, together with previously announced contracts, represents a major1 award for the company. The Coral Norte Floating Liquefied Natural Gas (FLNG) project, located offshore Mozambique and developed by Eni and its Partners CNPC, ENH, XRG, and KOGAS, is designed to produce approximately 3.6 Mtpa2 of LNG, doubling the Coral hub’s capacity to 7 Mtpa. This expansion positions Mozambique among Africa’s top three LNG producers, further strengthening the country’s role in the global energy market. Coral Norte is designed as an enhanced...

Continue reading

Share repurchase programme: Transactions of week 23 2026

The share repurchase programme runs as from 5 February 2026 and up to and including 29 January 2027 at the latest. In this period, Jyske Bank will acquire shares with a value of up to DKK 3 billion, cf. Corporate Announcement No. 11/2026 of 5 February 2026. The share repurchase programme is initiated and structured in compliance with the Market Abuse Regulation (Regulation (EU) No 596/2014) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (together with the Market Abuse Regulation, the “Safe Harbour Rules”). The following transactions have been made under the program:  Number of shares Average purchase price (DKK) Transaction value (DKK)Accumulated, previous announcement 1,109,017 904.55 1,003,161,2881 June 2026 12,924 909.66 11,756,4612 June 2026 12,080 902.32 10,900,0363 June 2026 13,162 894.72 11,776,3554...

Continue reading

Yeahka (9923.HK) Q1 Overseas Payment GPV Surges Nearly Fourfold to RMB2,439 Million

SHENZHEN, China, June 08, 2026 (GLOBE NEWSWIRE) — Yeahka Limited (Yeahka, Stock Code: 9923.HK) released its first quarter 2026 business update on June 5, coinciding with its Annual General Meeting. The Company achieved substantial commercialization progress across all business lines during the quarter, with overseas gross payment volume (GPV) growing approximately four times year-on-year, and the proportion of overseas profit contribution to the overall payment business exceeding 10% for the first time, reaching a record high. Overseas GPV reached RMB2,439 million in Q1 2026, roughly four times that of the same period last year, driven by localized teams delivering innovative products and services tailored to pain points in local vertical industries, as well as expanded project collaboration with strategic partners. The proportion...

Continue reading

Telenor receives approval to acquire GlobalConnect’s consumer business in Norway

(Fornebu, 8 June 2026) The Norwegian Competition Authority has approved Telenor’s acquisition of GlobalConnect’s Norwegian fibre business for residential customers. The transaction is valued at NOK 6 billion and is approved subject to remedies. “This transaction strengthens Telenor’s position in the Norwegian broadband market and is good for customers and for market development. Whilst we disagree that remedies were necessary, we are pleased to have reached a resolution. We look forward to welcoming 125,000 new customers to Telenor”, says Benedicte Schilbred Fasmer, President and CEO of Telenor. Conditions for approval As a condition of approval, Telenor and GlobalConnect are required to implement the following measures:GlobalConnect’s fibre infrastructure at addresses where Telenor also offers fibre shall be...

Continue reading

Ingredion Announces Recommended All-Cash Acquisition of Tate & Lyle

Creates a scaled global provider of specialty ingredient solutions for a healthier, tastier and more sustainable future of food  Broadens Ingredion’s specialty ingredients platform across texturants, sugar reduction, and fortification, adding complementary capabilities in multi-ingredient systems and recipe development Expands Ingredion’s ability to address customer needs across a wider range of end use categories and applications Brings together complementary geographic supply networks across the Americas, Europe, the Middle East and Africa, and Asia Pacific to deliver faster, more reliable and cost-effective ingredients and solutions for customers and consumers worldwideWESTCHESTER, Ill., June 08, 2026 (GLOBE NEWSWIRE) — Ingredion Incorporated (NYSE: INGR) (“Ingredion”), a leading global provider of ingredient solutions to...

Continue reading

Vivoryon Therapeutics N.V. to Report Q1 2026 Financial Results on June 11, 2026

Vivoryon Therapeutics N.V. to Report Q1 2026 Financial Results on June 11, 2026 Halle (Saale) / Munich, Germany, June 8, 2026 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company developing small molecule medicines for inflammatory and fibrotic disorders, with a primary focus on kidney diseases, today announced that it will publish its first quarter financial results for the period ended March 31, 2026 on Thursday, June 11, 2026. The Company’s next financial and business update conference call / webcast will be held in conjunction with the publication of its H1 results, anticipated in August.   ### About Vivoryon Therapeutics N.V.Vivoryon is a clinical stage biotechnology company focused on developing innovative small molecule-based medicines for the treatment of inflammatory and...

Continue reading

TGS Acquires Apparition Geoservices to Deliver a Step-Change in Seismic Efficiency and Subsurface Imaging

OSLO, Norway (8 June 2026) – TGS, a leading global provider of energy data and intelligence, today announced the acquisition of Apparition Geoservices GmbH, securing exclusive access to its proprietary simultaneous source acquisition and separation technology. Combined with TGS’ Gemini Enhanced Frequency Source (EFS) technology, Apparition creates a platform for step-change improvements in seismic operational efficiency, source capacity and subsurface imaging clarity. Apparition is an advanced seismic acquisition and processing methodology that enables multiple sound sources to operate simultaneously in a controlled, coordinated manner. Unlike traditional dithering approaches, it uses precise timing to encode sources distinctly, making overlapping signals easier to separate and cleaner to process. This increases acquisition efficiency...

Continue reading

IBA signs contract with a major U.S. academic medical center to install two Proteus®ONE proton therapy solutions

Louvain-La-Neuve, Belgium, June 08, 2026 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world’s leading provider of proton therapy solutions for the treatment of cancer, today announces the signing of a contract with Duke University Health System for the installation of two Proteus®ONE1 compact proton therapy solutions at the Duke Proton Center in Durham, NC, USA. The two Proteus®ONE systems will be installed side by side in a configuration designed to maximize clinical availability, operational flexibility, and patient treatment efficiency. As the market-leading compact proton therapy solution, Proteus®ONE is designed to continuously evolve and integrate the latest technological advancements, enabling IBA users to benefit from cutting-edge innovation and adaptable capabilities....

Continue reading

Nurix Therapeutics Announces Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and Neurology

Strategic collaboration combines Nurix’s leadership in targeted protein degradation with Roche’s portfolio of B-cell targeted therapies and global clinical and commercialization footprint Robust clinical development plan in malignant hematology builds on the ongoing pivotal program in chronic lymphocytic leukemia (CLL) and includes therapeutic combination regimens across B cell malignancies Clinical development plan also includes expansion into neurology and immunology with plans for Phase 2 trials in multiple sclerosis (MS) and chronic spontaneous urticaria (CSU) Nurix to receive an upfront cash payment of $700 million and is eligible to receive development, regulatory and sales milestones for potential total payments of up to $2.3 billion; profits and losses to be shared equally in the United States with Nurix receiving royalties on...

Continue reading

Nyrstar NV provides an update with regards to the Antwerp criminal investigation

Regulated Information – Inside information Nyrstar NV provides an update with regards to the Antwerp criminal investigation 8 June 2026 at 07.00 CEST Nyrstar NV (the “Company”) was notified on 6 June 2026 by the office of the investigating judge in Antwerp that, in connection with the ongoing criminal investigation, the Company has been formally placed under suspicion for alleged forgery and the use of false annual accounts, as well as for alleged misuse of corporate assets. The Company notes that it has not yet been granted access to the criminal file and is therefore not in a position to comment further on the allegations or the underlying facts at this time. The Company continues to provide its full cooperation with the ongoing criminal investigation in Antwerp. About Nyrstar NV The Company is incorporated in Belgium and...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.